Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus. From Wikipedia
Real-world data show that passive immunity from a single dose significantly lowers RSV-related hospital visits in Europe’s youngest infants
